Cambridge, UK, 5 September 2005 CellCentric, a leading company in the exploitation of epigenetics, announces that it has received new funding of £150,000 from NESTA (the National Endowment for Science, Technology and the Arts). The investment will be used to increase the company’s discovery capacity for epigenetic related cancer targets and therapeutics.
